Pimecrolimus Interferes the Therapeutic Efficacy of Human Mesenchymal Stem Cells in Atopic Dermatitis by Regulating NFAT-COX2 Signaling

0
128
Researchers investigated whether coadministration with pimecrolimus, one of the topical calcineurin inhibitors, could influence the therapeutic potential of human umbilical cord blood MSCs in atopic dermatitis.
[Stem Cell Research & Therapy]
Shin, N., Jung, N., Lee, S.-E., Kong, D., Kim, N. G., Kook, M. G., Park, H., Choi, S. W., Lee, S., & Kang, K.-S. (2021). Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling. Stem Cell Research & Therapy, 12(1), 482. https://doi.org/10.1186/s13287-021-02547-8 Cite
Full Article